Dal Pan GJ, Lindquist M, Gelperin K. Postmarketing spontaneous pharmacovigilance reporting systems. In: Strom BL, Kimmel SE, Hennessy S, editors. Textbook of pharmacoepidemiology. 2021. pp. 113–35.

Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;3(16):495.

Article  Google Scholar 

Blanco C, Olfson M, Goodwin RD, Ogburn E, Liebowitz MR, Nunes EV, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry. 2008;69(8):1276–80.

Article  PubMed  Google Scholar 

Tahhan AS, Vaduganathan M, Greene SJ, Alrohaibani A, Raad M, Gafeer M, et al. Enrollment of older patients, women, and racial/ethnic minority groups in contemporary acute coronary syndrome clinical trials: a systematic review. JAMA Cardiol. 2020;5(6):714–22.

Article  PubMed  Google Scholar 

Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10): e191870.

Article  PubMed  PubMed Central  Google Scholar 

Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–6.

Article  CAS  PubMed  Google Scholar 

Chamberlain C, Kortepeter C, Muñoz M. Clinical analysis of adverse drug reactions and pharmacovigilance. In: Huang S-M, Lertora JJL, Vicini P, Atkinson AJ, editors. Atkinson's principles of clinical pharmacology. 2022. pp. 499–517.

Lester J, Neyarapally GA, Lipowski E, Graham CF, Hall M, Dal Pan G. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf. 2013;22(3):302–5.

Article  PubMed  Google Scholar 

Ishiguro C, Hall M, Neyarapally GA, Dal Pan G. Post-market drug safety evidence sources: an analysis of FDA drug safety communications. Pharmacoepidemiol Drug Saf. 2012;21(10):1134–6.

Article  PubMed  Google Scholar 

Croteau D, Pinnow E, Wu E, Munoz M, Bulatao I, Dal Pan G. Sources of evidence triggering and supporting safety-related labeling changes: a 10-year longitudinal assessment of 22 new molecular entities approved in 2008 by the US Food and Drug Administration. Drug Saf. 2022;45(2):169–80.

Article  PubMed  Google Scholar 

Best practices in drug and biological product postmarket safety surveillance for FDA staff. January 2024. Available: https://www.fda.gov/media/130216/download.

21 CFR 310.305 (prescription drugs marketed for human use without an approved application), 21 CFR 314.80 (human drugs with approved NDAs), 21 CFR 314.98 (human drugs with approved ANDAs), 21 CFR 600.80 (human biological products with approved BLAs), section 760 of the FD&C Act (nonprescription human drug products marketed without an approved application), and 21 CFR Part 4, Subpart B (combination products). Available: http://www.regulations.gov.

MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program. Accessed 4 July 2021.

Inacio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83(2):227–46.

Article  PubMed  Google Scholar 

van Hunsel F, Harmark L, Rolfes L. Fifteen years of patient reporting—what have we learned and where are we heading to? Expert Opin Drug Saf. 2019;18(6):477–84.

Article  PubMed  Google Scholar 

Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ, Yellow Card Study C. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK’s Yellow Card Scheme. Drug Saf. 2013;36(3):199–206.

Article  PubMed  Google Scholar 

Harmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug Saf. 2015;38(4):337–47.

Article  PubMed  Google Scholar 

Harmark L, van Puijenbroek E, van Grootheest K. Intensive monitoring of duloxetine: results of a web-based intensive monitoring study. Eur J Clin Pharmacol. 2013;69(2):209–15.

Article  PubMed  Google Scholar 

Harmark L, van Puijenbroek E, Straus S, van Grootheest K. Intensive monitoring of pregabalin: results from an observational, web-based, prospective cohort study in the Netherlands using patients as a source of information. Drug Saf. 2011;34(3):221–31.

Article  CAS  PubMed  Google Scholar 

Munoz MA, Delcher C, Dal Pan GJ, Kortepeter CM, Wu E, Wei YJ, et al. Impact of a new consumer form on the quantity and quality of adverse event reports submitted to the United States Food and Drug Administration. Pharmacotherapy. 2019;39(11):1042–52.

Article  PubMed  Google Scholar 

Avery A, Anderson C, Bond C, Fortnum H, Gifford A. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):234.

Article  Google Scholar 

German RR, Lee LM, Horan JM, Milstein RL, Pertowski CA, Waller MN, et al. Updated guidelines for evaluating public health surveillance systems: recommendations from the Guidelines Working Group. MMWR Recomm Rep. 2001;50(RR-13):1–35.

CAS  PubMed  Google Scholar 

McAdams M, Staffa J, Dal Pan G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2008;17(3):229–39.

Article  CAS  PubMed  Google Scholar 

Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2017;83(4):875–83.

Article  PubMed  Google Scholar 

Agency for Healthcare Research and Quality. 2019 National Healthcare Quality and Disparities Report. Available: https://www.ahrq.gov/research/findings/nhqrdr/nhqdr19/index.html. Accessed 5 Sept 2021.

Institute of Medicine. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: National Academies Press; 2003.

Google Scholar 

Serchen J, Doherty R, Atiq O, Hilden D, Health, Public Policy Committee of the American College of P. A comprehensive policy framework to understand and address disparities and discrimination in health and health care: a policy paper from the American College of Physicians. Ann Intern Med. 2021;174(4):529–32.

Article  PubMed  Google Scholar 

Hall-Lipsy EA, Chisholm-Burns MA. Pharmacotherapeutic disparities: racial, ethnic, and sex variations in medication treatment. Am J Health Syst Pharm. 2010;67(6):462–8.

Article  CAS  PubMed  Google Scholar 

McQuaid EL, Landier W. Cultural issues in medication adherence: disparities and directions. J Gen Intern Med. 2018;33(2):200–6.

Article  PubMed  Google Scholar 

FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm. Accessed: 13 Feb 2022.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Efficacy guidelines. Available: https://www.ich.org/page/efficacy-guidelines. Accessed: 21 Feb 2022.

MedWatch forms for FDA safety reporting. Available: https://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm. Accessed 8 Mar 2022.

HUD USPS ZIP Code Crosswalk Files. U.S. Department of Housing and Urban Development. Available: https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Accessed 4 Feb 2018.

County Health Rankings & Roadmaps. Robert Wood Johnson Foundation and University of Wisconsin Population Health Institute. Available: http://www.countyhealthrankings.org/. Accessed 6 Aug 2017.

Symphony Health Integrated Dataverse Placeholder. To be updated.

United States Census Bureau. American FactFinder. Available: https://factfinder.census.gov/. Accessed 4 June 2017.

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; MedWatch: The Food and Drug Administration Medical Products Reporting Program. Available: https://www.regulations.gov/document?D=FDA-2014-N-1960-0002. Accessed 6 Aug 2017.

21 CFR 201.57. Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1). Available: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.57. Accessed 4 Apr 2023.

The Food and Drug Administration Amendments Act of 2007 (Public Law 110-85), amending the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §301.

Rikard RV, Thompson MS, McKinney J, Beauchamp A. Examining health literacy disparities in the United States: a third look at the National Assessment of Adult Literacy (NAAL). BMC Public Health. 2016;13(16):975.

Article  Google Scholar 

Sentell T, Braun KL. Low health literacy, limited English proficiency, and health status in Asians, Latinos, and other racial/ethnic groups in California. J Health Commun. 2012;17(Suppl 3):82–99.

Article  PubMed  PubMed Central  Google Scholar 

United States Federal Register. Agency Information Collection Activities; Proposed Collection; Comment Request; MedWatch: The Food and Drug Administration Medical Products Reporting Program. Available: https://www.federalregister.gov/documents/2021/06/30/2021-13943/agency-information-collection-activities-proposed-collection-comment-request-medwatch-the-food-and. Accessed 12 Sept 2021.

Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17: 100188.

Article  PubMed  PubMed Central  Google Scholar 

Bolin JN, Bellamy G, Ferdinand AO, Kash BA, Helduser JW, editors. Rural healthy people 2020, vol 1. College Station: Texas A&M Health Science Center School of Public Health, Southwest Rural Health Research Center; 2015. Available: https://srhrc.tamhsc.edu/docs/rhp2020-volume-1.pdf. Accessed: 15 Apr 2018.

Inacio P, Gomes JJ, Airaksinen M, Cavaco A. Exploring sociodemographic and economic factors that promote adverse drug reactions reporting by patients. Health Policy. 2018;122(3):263–8.

Article  PubMed  Google Scholar 

Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46(1):49–53.

Article  PubMed  PubMed Central  Google Scholar 

Yadesa TM, Kitutu FE, Deyno S, Ogwang PE, Tamukong R, Alele PE. Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: a systematic review and meta-analysis. SAGE Open Med. 2021;9:20503121211039100.

Article  PubMed  PubMed Central  Google Scholar 

Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22.

Article  PubMed  PubMed Central  Google Scholar 

Jenkins MR, Munoz MA, Bak D, Chai G, Ready T, South EM, et al. Food and Drug Administration beyond the 2001 Government Accountability Office Report: promoting drug safety for women. J Womens Health (Larchmt). 2021;30(7):927–34.

Article  PubMed  Google Scholar 

FDA Drug Safety Communication. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). Available: https://wayback.archive-it.org/7993/20170404172106/https://www.fda.gov/Drugs/DrugSafety/ucm334033.htm. Accessed 19 Mar 2022.

Cohen RA, Boersma P, Vahratian A. Strategies used by adults aged 18–64 to reduce their prescription drug costs, 2017. NCHS Data Brief. 2019;333:1–8.

Google Scholar 

Institute of Medicine (US) Committee on the Consequences of Uninsurance. Care without coverage: too little, too late. National Academies Press (US); 2002. https://doi.org/10.17226/10367.

Woolhandler S, Himmelstein DU. The relationship of health insurance and mortality: is lack of insurance deadly? Ann Intern Med. 2017;167(6):424–31.

Article  PubMed